Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605891 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study of CHF 4226 for Treating Patients With COPD
A Phase 2 study, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 278
- Enrollment target
NCT00605891 is a Phase 2 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 278 participants.
The verdict
NCT00605891, a Phase 2 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 278 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.
Interventions
- DRUG placebo
- DRUG carmoterol (CHF 4226)
- DRUG salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605891
The ClinicalTrials.gov registry entry for NCT00605891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00605891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605891 about?
NCT00605891 is a clinical study titled "Dose Finding Study of CHF 4226 for Treating Patients With COPD". The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.
What is the current status of trial NCT00605891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2006-10. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00605891?
The interventions under investigation include: placebo (DRUG), carmoterol (CHF 4226) (DRUG), salmeterol (DRUG).
Who is sponsoring clinical trial NCT00605891?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.